A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Autor: Gemici A; Department of Hematology, Medipol University, Istanbul, Turkey. Electronic address: inci.alacaciogl@deu.edu.tr., Ozkalemkas F; Department of Hematology, Uludağ University, Bursa, Turkey., Dogu MH; Department of Hematology, Istinye University, Istanbul, Turkey., Tekinalp A; Department of Hematology, Necmettin Erbakan University, Konya, Turkey., Alacacioglu I; Department of Hematology, Dokuz Eylul University, Izmir, Turkey., Guney T; Department of Hematology, University of Medical Sciences, Ankara City Hospital, Ankara, Turkey., Ince I; Division of Hematology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkey., Geduk A; Department of Hematology, Kocaeli University, Kocaeli, Turkey., Cagliyan GA; Department of Hematology, Pamukkale University, Denizli, Turkey., Maral S; Division of Hematology, Diskapi Training and Research Hospital, Ankara, Turkey., Serin I; Division of Hematology, Istanbul Training and Research Hospital, Istanbul, Turkey., Gunduz E; Department of Hematology, Osman Gazi University, Eskisehir, Turkey., Karakus V; Department of Hematology, Alaaddin Keykubat University, Alanya, Turkey., Bekoz HS; Department of Hematology, Medipol University, Istanbul, Turkey., Eren R; Division of Hematology, Bozyaka Training and Research Hospital, Izmir, Turkey., Pinar IE; Department of Hematology, Uludağ University, Bursa, Turkey., Gunes AK; Department of Hematology, University of Medical Sciences, Ankara City Hospital, Ankara, Turkey., Sargın FD; Department of Hematology, Medipol University, Istanbul, Turkey., Sevindik OG; Department of Hematology, Medipol University, Istanbul, Turkey.
Jazyk: angličtina
Zdroj: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2021 Aug; Vol. 21 (8), pp. e686-e692. Date of Electronic Publication: 2021 Apr 20.
DOI: 10.1016/j.clml.2021.04.004
Abstrakt: Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML.
Materials and Methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML.
Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported.
Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: